arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Atea Pharmaceuticals, Inc.

AVIR

$5.27 ▲ +0.26 (+5.19%) at close

9 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Atea Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $429.5M

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -63.2% ↘

FCF / Share $-1.62 →

Trailing P/E —

Price / Book 1.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$351.37M

↑ +622.5% —

Net Income Profit after all expenses

$-158.35M

↑ +6.0% —

Operating Margin Operating profit as % of sales

39.4%

↑ +273.6% —

FCF / Share Free cash flow per share

$-1.62

↓ -0.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue Growth YoY (%)	—	—	—	—	622.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+7681%)	—	—	—	—
EPS Growth YoY (%)	3.0% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	-22.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-17.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	—	—	—	—
Net Income Growth YoY (%)	6.0% Fair ↑ Fair Improving Year-over-year change in net income	-23.9% Weak Weak Year-over-year change in net income	-17.3% Weak Weak Year-over-year change in net income	N/M	N/M	22.0% Good Good Year-over-year change in net income	-54.8% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-0.8% Weak ↑ Weak Improving Year-over-year change in free cash flow	-57.0% Weak ↓ Weak Declining Year-over-year change in free cash flow	30.7% Excellent Excellent Year-over-year change in free cash flow	-40.6% Weak Weak Year-over-year change in free cash flow	N/M	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Operating Margin (%) (%)	—	—	—	—	39.4% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+163%)	-22.7% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-251%)	—	—	—
Effective Tax Rate (%) (%)	3.7% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.6% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.8% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	3.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	12.6% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—
Profit Margin (%) (%)	—	—	—	—	34.5% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+187%)	-22.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-288%)	—	—	—
FCF Margin (%) (%)	—	—	—	—	-24.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.83x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.63x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	1.06x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	-0.72x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-27.10x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	-63.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-44.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-29.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-19.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	17.0% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-1.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	23.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	20.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-57.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-41.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-27.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-19.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	17.9% Excellent ↑ Excellent Improving Operating profit relative to total assets Optimal: > 10%	-1.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-66.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-57.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-483%)	-38.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-356%)	-24.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-263%)	-18.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-221%)	17.1% Good → Good Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+14%)	-2.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-113%)	28.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+89%)	25.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+67%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Net Debt (USD)	$-95.71M	$-64.70M	$-143.82M	$-188.46M	$-764.38M	$-850.12M	$-21.66M	$-34.49M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue per Share (USD)	—	—	—	—	$4.24	$2.25	—	—	—
Basic EPS, GAAP (USD)	$-1.94	$-2.00	$-1.63	$-1.39	$1.46	$-0.51	—	—	—
Free Cash Flow per Share (USD)	$-1.62	$-1.61	$-1.02	$-1.48	$-1.05	$13.74	—	—	—
Book Value per Share (USD)	$3.53	$5.20	$6.65	$7.69	$8.54	$6.65	$-4.91	—	—
Tangible Book Value per Share (USD)	$3.53	$5.20	$6.65	$7.69	$8.54	$6.65	$-4.91	—	—
Basic Weighted Avg Shares (shares)	81.50M	84.26M	83.39M	83.25M	82.82M	21.59M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$271.21M	$443.75M	$558.08M	$642.44M	$715.52M	$547.68M	$19.48M	—	—
Total Equity (USD)	$275.43M	$438.87M	$555.19M	$640.57M	$710.08M	$547.80M	$-49.57M	$-36.16M	$-27.51M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	$351.37M	$48.63M	—	—	—
Net Income, GAAP (USD)	$-158.35M	$-168.38M	$-135.96M	$-115.91M	$121.19M	$-10.95M	$-14.03M	$-9.06M	—
Operating Cash Flow (USD)	$-132.03M	$-135.50M	$-85.39M	$-120.98M	$-87.00M	$296.73M	$-12.83M	$-7.91M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 31 quarters

Atea Pharmaceuticals, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare AVIR with peers